What is the equivalent of Breo Ellipta (fluticasone furoate-vilanterol) 200 micrograms-25 micrograms 1 puff daily in Anoro Ellipta (umeclidinium-vilanterol)?

From the Guidelines

The equivalent of Breo Ellipta 200 mcg-25 mcg 1 puff daily in Anoro Ellipta would be Anoro Ellipta 62.5 mcg-25 mcg 1 puff daily. However, these medications contain different active ingredients and are not direct substitutes for each other. Breo Ellipta contains fluticasone furoate (an inhaled corticosteroid) and vilanterol (a long-acting beta-agonist or LABA), while Anoro Ellipta contains umeclidinium (a long-acting muscarinic antagonist or LAMA) and vilanterol (LABA) 1. The only common component is vilanterol at the same 25 mcg dose. Some key points to consider when comparing these medications include:

• The presence of an inhaled corticosteroid in Breo Ellipta, which is not present in Anoro Ellipta
• The presence of a long-acting muscarinic antagonist in Anoro Ellipta, which is not present in Breo Ellipta
• The potential for worsening symptoms if the inhaled corticosteroid component is removed, as this could lead to decreased control of inflammation in the airways. Switching between these medications should only be done under medical supervision as they treat respiratory conditions differently. It's also important to note that the study by the American College of Chest Physicians and Canadian Thoracic Society guideline discusses the use of novel therapies, including once-daily long-acting β-agonists and long-acting muscarinic antagonists, but does not provide direct guidance on equivalent dosing between Breo Ellipta and Anoro Ellipta 1.

From the Research

Equivalent Dosing of Anoro Ellipta to Breo Ellipta

• The equivalent of Breo Ellipta 200 mcg-25 mcg 1 puff daily in Anoro Ellipta is not directly stated in the provided studies 2, 3, 4, 5, 6.
• However, it can be noted that Breo Ellipta contains fluticasone furoate and vilanterol, while Anoro Ellipta contains umeclidinium and vilanterol.
• Studies have compared the efficacy of triple therapy combinations, including fluticasone furoate/umeclidinium/vilanterol, to dual therapies in patients with COPD 2, 3, 4, 5, 6.
• The dosing of Anoro Ellipta is typically umeclidinium 62.5 mcg and vilanterol 25 mcg, administered once daily 3.
• There is no direct comparison of Breo Ellipta to Anoro Ellipta in terms of equivalent dosing in the provided studies.

Key Differences Between Breo Ellipta and Anoro Ellipta

• Breo Ellipta contains an inhaled corticosteroid (fluticasone furoate) and a long-acting beta-2 adrenoceptor agonist (vilanterol) 2.
• Anoro Ellipta contains a long-acting muscarinic antagonist (umeclidinium) and a long-acting beta-2 adrenoceptor agonist (vilanterol) 3.
• The combination of umeclidinium and vilanterol in Anoro Ellipta provides a different mechanism of action compared to Breo Ellipta, which may affect the equivalent dosing.

Conclusion Not Available

There are no research papers to assist in answering this question regarding the equivalent dosing of Anoro Ellipta to Breo Ellipta 200 mcg-25 mcg 1 puff daily.